Clinical Investigation Site Summary: St. Joseph Heritage Healthcare Treating Metastatic Castration Resistant Prostate Cancer

Nov 14, 2019 | Blog, Clinical Investigational Site, Clinical Investigator Site, Clinical Investigators, Metastatic Prostate Cancer, News

Clinical Investigation Site Summary St. Joseph Heritage Healthcare Treating Metastatic Castration Resistant Prostate Cancer

Let’s say, for example, your father was diagnosed with prostate cancer and referred to a clinical investigation site for a new investigational treatment. How would you know the quality of care being provided there, the experience of the doctors, their reputation for patient care, and so on? A lot of targeted research might get you some answers. But that’s where TrialSite News comes in. We are providing consolidated, researched information on various clinical investigation sites for patients and other interested parties. We have reviewed two other sites located in California, Pacific Hematology Oncology Associates and San Bernardino Urological Associates, that are currently participating in an ongoing clinical trial. Also participating is St. Joseph Heritage Healthcare, who we cover below.

About St. Joseph Heritage Healthcare

Part of Providence St. Joseph Health, St. Joseph Heritage Healthcare (Heritage) was founded in 1994 and includes eight medical groups throughout California. In addition to its medical groups, Heritage supports six distinct affiliated physician networks throughout the state. Combined, they provide residents access to more than 2,000 providers in virtually every specialty. Heritage medical groups and affiliated physicians have received top honors from various organizations, including the Orange County Medical Association for Physicians of Excellence and the Integrated Healthcare Association with distinction in clinical quality.

Their Medical Groups

Their Affiliate Networks

Heritage Quick Facts:

  • 915 Medical Group Providers
  • 1,327 Affiliate Providers
  • 175 Clinics
  • 3,900 Caregivers

Study Sponsor

Clovis Oncology, Inc. is sponsoring this study, officially titled “TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician’s Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency.” Founded in 2009, Clovis Oncology is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis believes this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.

Study Details and Participation

The actual study start date was in June 2017 and it’s estimated completion date is in April 2022. The estimated enrollment is 400 participants. It is currently recruiting participants, depending on location. St. Joseph Heritage Healthcare is still in the recruiting phase.

Key Principal Investigator

With nearly 4,000 caregivers under their employment at St. Joseph Heritage Healthcare, TrialSite News researchers could not pinpoint the key principal investigator involved in this particular clinical trial. We suggest that patients who are referred to their practice should call and ask that specific location who their principal investigator is.

The google listing for their corporate office has mostly positive reviews; however, we could not find an official Yelp page or Facebook page.

Call to Action: Learn more about clinical investigation sites by signing up for our Daily Digest. Get in touch with us, too, if you have a specific site you’d like more information on.

0 Comments

Pin It on Pinterest